Prostate Cancer Trial, Recruiting NCT06914544 Sponsor: University Hospital Schleswig-Holstein Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT06914544
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with prostate cancer that has not spread beyond the prostate (confirmed by a tissue biopsy)
  • Your cancer is at an early, localised stage (stages cT1 to T2c, with no spread to lymph nodes or other parts of the body)
  • Your cancer grade is considered low to intermediate (Gleason score of 7 or below, or ISUP Grade Group 1–3)
  • Your cancer has been assessed and staged using standard medical guidelines
  • You are 18 years of age or older
  • Your PSA level (a prostate-related protein measured in a blood test) is below 20 ng/ml
  • The size of your prostate is smaller than 80 cm³ (a measurement usually taken by scan)
  • Your urinary symptom score (a questionnaire about bladder and urination issues) is 12 or below
  • You are willing and able to give written consent to take part

Who may not be able to join:

  • You have previously had radiotherapy to the pelvic area (the lower abdomen/hip region)
  • You have previously had certain prostate procedures, including keyhole surgery through the urethra, laser treatment, or prostate tissue removal
  • You have a reason why you cannot have an MRI scan or cannot have small marker implants placed in your prostate — for example, a gold allergy (confirm with trial site)
  • You have a serious health condition that may make it difficult to complete the treatment as required (confirm with trial site)
  • You are not legally able to give consent, or you are unwilling to provide written informed consent

⚠️ Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 16 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: David Krug, MD, University Hospital Schleswig-Holstein

Phone: +4943150026666

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Hospital Schleswig-Holstein
Registry
ClinicalTrials.gov
Start date
10 December 2025
Est. completion
31 December 2028

Where this trial is recruiting

🇩🇪 Germany

Primary endpoints

GU and GI Toxicity

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 16 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov